Market Closed -
Nasdaq
21:00:00 30/04/2024 BST
|
5-day change
|
1st Jan Change
|
20.35
USD
|
-1.12%
|
|
-1.41%
|
-29.61%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
270.9
|
1,265
|
3,001
|
900.1
|
856.7
|
608.5
|
-
|
-
|
Enterprise Value (EV)
1 |
258.9
|
980.3
|
3,001
|
379.5
|
433.7
|
-191.5
|
-146.3
|
-101.6
|
P/E ratio
|
-645
x
|
5.85
x
|
6.14
x
|
6.43
x
|
-5.13
x
|
-8.81
x
|
-10.8
x
|
-11.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
8.33
x
|
3
x
|
3.02
x
|
1.45
x
|
2.96
x
|
2.18
x
|
1.89
x
|
1.73
x
|
EV / Revenue
|
7.96
x
|
2.32
x
|
3.02
x
|
0.61
x
|
1.5
x
|
-0.69
x
|
-0.45
x
|
-0.29
x
|
EV / EBITDA
|
53.3
x
|
3.25
x
|
4.27
x
|
1.48
x
|
288
x
|
7.38
x
|
14.2
x
|
-50
x
|
EV / FCF
|
61,675,894
x
|
9,415,324
x
|
-
|
1,616,672
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
0%
|
0%
|
-
|
0%
|
-
|
-
|
-
|
-
|
Price to Book
|
3.36
x
|
2.58
x
|
-
|
0.69
x
|
0.76
x
|
0.55
x
|
0.57
x
|
0.58
x
|
Nbr of stocks (in thousands)
|
20,998
|
24,274
|
29,831
|
30,225
|
29,633
|
29,901
|
-
|
-
|
Reference price
2 |
12.90
|
52.10
|
100.6
|
29.78
|
28.91
|
20.35
|
20.35
|
20.35
|
Announcement Date
|
10/03/20
|
04/03/21
|
23/02/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
32.53
|
421.7
|
992.6
|
619
|
289.2
|
279.4
|
321.5
|
350.8
|
EBITDA
1 |
4.854
|
301.3
|
703.6
|
257.1
|
1.504
|
-25.95
|
-10.3
|
2.03
|
EBIT
1 |
-0.428
|
290.2
|
676
|
178.5
|
-195.5
|
-83.85
|
-74.01
|
-64.15
|
Operating Margin
|
-1.32%
|
68.8%
|
68.1%
|
28.84%
|
-67.61%
|
-30.02%
|
-23.02%
|
-18.29%
|
Earnings before Tax (EBT)
1 |
0.409
|
291.7
|
677.3
|
184
|
-174.1
|
-86.94
|
-74.66
|
-81
|
Net income
1 |
-0.411
|
214.3
|
507.4
|
143.4
|
-167.8
|
-69.35
|
-58.5
|
-57
|
Net margin
|
-1.26%
|
50.82%
|
51.12%
|
23.17%
|
-58.03%
|
-24.82%
|
-18.19%
|
-16.25%
|
EPS
2 |
-0.0200
|
8.910
|
16.38
|
4.630
|
-5.630
|
-2.310
|
-1.885
|
-1.730
|
Free Cash Flow
|
4.198
|
104.1
|
-
|
234.7
|
-
|
-
|
-
|
-
|
FCF margin
|
12.91%
|
24.69%
|
-
|
37.93%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
86.49%
|
34.56%
|
-
|
91.3%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
48.58%
|
-
|
163.7%
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/03/20
|
04/03/21
|
23/02/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
227.9
|
251.7
|
320.3
|
125.3
|
105.7
|
67.7
|
66.17
|
67.85
|
84.69
|
70.5
|
65.36
|
69.06
|
71.06
|
73.91
|
75.88
|
EBITDA
1 |
167.3
|
159.8
|
213.4
|
31.05
|
10.17
|
-15.08
|
-7.168
|
-2.707
|
18.14
|
-6.759
|
-9.241
|
-6.778
|
-3.711
|
-6.219
|
-5.676
|
EBIT
1 |
160.1
|
150.8
|
201.9
|
12.79
|
0.352
|
-36.55
|
-24.82
|
-19.8
|
0.214
|
-151.1
|
-22.31
|
-20.94
|
-19.32
|
-20.95
|
-20.44
|
Operating Margin
|
70.25%
|
59.93%
|
63.05%
|
10.21%
|
0.33%
|
-53.99%
|
-37.52%
|
-29.18%
|
0.25%
|
-214.34%
|
-34.13%
|
-30.33%
|
-27.19%
|
-28.34%
|
-26.94%
|
Earnings before Tax (EBT)
1 |
159.8
|
150.8
|
202
|
13.75
|
1.757
|
-33.46
|
-21.05
|
-14.7
|
6.86
|
-145.2
|
-22.89
|
-21.55
|
-19.64
|
-22.36
|
-20.61
|
Net income
1 |
122.5
|
104.3
|
154
|
11.54
|
1.719
|
-23.83
|
-15.34
|
-11.23
|
-13.11
|
-128.1
|
-18.2
|
-17.39
|
-16.03
|
-17.73
|
-16.1
|
Net margin
|
53.77%
|
41.46%
|
48.08%
|
9.2%
|
1.63%
|
-35.2%
|
-23.18%
|
-16.55%
|
-15.48%
|
-181.76%
|
-27.85%
|
-25.18%
|
-22.55%
|
-23.99%
|
-21.21%
|
EPS
2 |
3.930
|
3.340
|
4.930
|
-
|
0.0600
|
-0.8000
|
-0.5200
|
-0.3800
|
-0.4400
|
-4.300
|
-0.6150
|
-0.5750
|
-0.5250
|
-0.5850
|
-0.5300
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/11/21
|
23/02/22
|
03/05/22
|
04/08/22
|
07/11/22
|
28/02/23
|
05/05/23
|
04/08/23
|
03/11/23
|
28/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
12
|
284
|
-
|
521
|
423
|
800
|
755
|
710
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
4.2
|
104
|
-
|
235
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
5.4%
|
65.7%
|
-
|
14.8%
|
-14%
|
-2.89%
|
-2.95%
|
-2.81%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
3.840
|
20.20
|
-
|
43.00
|
38.10
|
36.90
|
35.80
|
34.80
|
Cash Flow per Share
|
-
|
5.850
|
-
|
8.190
|
-
|
-
|
-
|
-
|
Capex
1 |
1.32
|
36.5
|
-
|
18.8
|
22.2
|
25.9
|
29.8
|
34.6
|
Capex / Sales
|
4.05%
|
8.66%
|
-
|
3.03%
|
7.68%
|
9.27%
|
9.25%
|
9.88%
|
Announcement Date
|
10/03/20
|
04/03/21
|
23/02/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Last Close Price
20.35
USD Average target price
26.67
USD Spread / Average Target +31.04% Consensus |
1st Jan change
|
Capi.
|
---|
| -29.61% | 608M | | -17.39% | 8.35B | | +39.49% | 3.58B | | -38.71% | 2.46B | | -8.06% | 2.47B | | -7.96% | 2.36B | | -13.97% | 1.78B | | -19.73% | 1.53B | | -40.78% | 1.21B | | +8.32% | 1.12B |
Medical & Diagnostic Laboratories
|